key: cord-0991673-49em7ji4
authors: Fujiwara, Sho; Nakajima, Mikio; Kaszynski, Richard H.; Fukushima, Kazuaki; Tanaka, Masaru; Yajima, Keishiro; Kobayashi, Taiichiro; Sekiya, Noritaka; Yamamoto, Yasuhiro; Miwa, Maki; Ishihata, Ayaka; Yamauchi, Yuko; Yamamoto, Kazuo; Goto, Hideaki; Imamura, Akifumi
title: Prevalence of thromboembolic events and status of prophylactic anticoagulant therapy in hospitalized patients with COVID-19 in Japan
date: 2021-02-19
journal: J Infect Chemother
DOI: 10.1016/j.jiac.2021.02.019
sha: 589acbb8a2b57bc30344077d4e8fac05b1e80cc3
doc_id: 991673
cord_uid: 49em7ji4

INTRODUCTION: One of the most prominent and concerning complications associated with coronavirus disease 2019 (COVID-19) is venous and arterial thromboembolisms. The aim of the present study was to delineate the prevalence of thromboembolic events and the current status of prophylactic anticoagulation therapy in patients with COVID-19 in Japan. METHODS: Between February 1 and August 31, 2020, we performed a dual-center, retrospective cohort study based on data obtained from the medical charts of COVID-19 patients admitted to healthcare facilities in Japan. The primary outcome was any thromboembolic events, including pulmonary embolism (PE), deep vein thrombosis (DVT), myocardial infarction, ischemic stroke and other systemic thromboemboli. RESULTS: During the study period, we extracted 628 consecutive patients admitted for COVID-19. Prophylactic anticoagulant therapy was administered in 63 (10%) patients of whom 20 (31.7%) were admitted to the intensive care unit (ICU). Thromboembolic events occurred in 18 (2.9%) patients (14.3% of patients in ICU and 2.2% of patients in the general wards). DVT were detected in 13 (2.1%) patients, PE in 11 (1.8%), and both DVT and PE in 6 (0.96%). An increasing prevalence in thromboembolic events was noted with progression in clinical severity. Overall in-hospital mortality was 4.8%. CONCLUSIONS: Prophylactic anticoagulation therapy was administered in only 10% of all hospitalized COVID-19 patients. The prevalence of any thromboembolic events was 2.9% in COVID-19 patients with most events occurring in severe and critical patients. Therefore, prophylactic anticoagulation therapy may be warranted in severe and critical patients but in asymptomatic to moderate patients the practice remains controversial.

patients hospitalized with COVID-19 and found that VTE events occurred in 6.2% of all hospitalized patients and 13.6% of ICU patients. [2] In this particular study, the vast majority of patients were administered anticoagulation agents in a prophylactic capacity, regardless of clinical severity of disease.

Several guidelines recommend the use of "universal" prophylactic anticoagulation therapy for all hospitalized patients with COVID-19. [3] [4] [5] [6] However, in non-COVID-19 patients, the prevalence of VTEs in Asian nations is approximately 3 to 5-fold lower in comparison with their western counterparts. [7, 8] Even fundamental evidence pertaining to the prevalence of VTEs and current status of prophylactic anticoagulation therapy in patients with COVID-19 in Japan is virtually non-existent. A study based on data derived from 2,638 patients hospitalized with COVID-19 included in a Japanese patient registry showed that the prevalence of DVT and PE were 0.9% and 0.5%, respectively. [9] The reported prevalence of DVT and PE were extremely low in comparison with existing studies; however, these registry-based studies assume the potential limitation of underreporting events. Therefore the present study aimed to describe the prevalence of thromboembolic events and the current status of prophylactic anticoagulation therapy based on a detailed review of institutional medical charts in patients with COVID-19 in Japan.

We performed a dual-center, retrospective cohort study based on data obtained from the healthcare facility and has been treating COVID-19 patients since the outbreak aboard the Diamond Princess cruise ship. Hiroo Hospital is one of the designated tertiary emergency medical centers in Tokyo and has primarily been tasked with the management of critically ill patients.

We included all patients with COVID-19 admitted to our hospitals during the defined timeframe. Patients under the age of 18 were excluded from the study. Clinical outcomes were followed up until discharge or September 30, 2020, whichever came first. All COVID-19 patients were diagnosed by a reverse transcription polymerase chain reaction test for SARS-CoV-2 via a nose or throat swab, sputum or saliva sample. (favipiravir, chloroquine, lopinavir-ritonavir and remdesivir), and prophylactic anticoagulants (unfractionated intravenous heparin, subcutaneous heparin calcium, direct oral anticoagulants and warfarin). We also described the severity of COVID-19 during hospitalization. Severity of disease was categorized using the Interim Guidance issued by the World Health Organization. In the guidance document, the severity of COVID-19 has been divided into five categories: asymptomatic, mild, moderate, severe and critical. [11] Additionally, we tabulated the number of patients who underwent computed tomographic pulmonary angiography (CTPA) and two-point proximal compression J o u r n a l P r e -p r o o f -12 -ultrasonography.

The primary outcome was the prevalence any thromboembolic event, including PE, DVT, myocardial infarction, ischemic stroke and other systemic thromboemboli. PE and DVT were diagnosed using computed tomographic pulmonary angiography (CTPA).

Screening for thromboemboli using CTPA and/or ultrasonography was not routinely performed in our facilities. CTPA was performed based on the judgement of each treating physician. A rapid increase of D-dimer, persistence of high levels of D-dimer, signs or symptoms of DVT or PE, and clinically unexplained reduction in P/F ratio, could trigger the decision to implement CTPA and/or ultrasonography. Two-point compression ultrasounds were performed by physicians at the bedside. Meanwhile, whole-leg ultrasounds conducted by clinical sonographers under normal operations were omitted from routine screening practice over concerns regarding potential transmission of COVID-19. [12] Secondary outcomes included in-hospital deaths and length of hospital stay.

Continuous variables are presented as medians with interquartile ranges (IQR), and J o u r n a l P r e -p r o o f -13 -categorical variables are reported as count and percentage. We compared various characteristics between patients experiencing any thromboembolic events versus those who did not. The chi-squared test or Fisher exact test were used to compare proportions.

Wilcoxon rank-sum test was adopted to compare continuous variables. A P-value of <0.05 was considered statistically significant. All analyses were performed using Stata MP15 (StataCorp, College Station, TX, USA).

Hospital (approval number, 2561 in Komagome Hospital and J-29 in Hiroo Hospital).

Owing to the anonymous nature of the retrospective data, we obtained informed consent in the form of an opt-out on the hospital's website.

During the study period, we extracted data from 628 consecutive patients admitted to either facility for COVID-19. Clinical characteristics at baseline and laboratory findings are reported in Table 1 An increasing prevalence in thromboembolic events was noted with progression in clinical severity.

In the present study, the overall prevalence of thromboembolic events was 2.9%.

Notable differences were observed depending on setting with 14.3% and 2.2% of patients experiencing these events in the ICU and general wards, respectively.

Prophylactic anticoagulant therapy was administered in only 10% of all hospitalized patients.

The prevalence of thromboembolic events in our study was much lower than that of previous studies conducted in western populations. [2, 13, 14] In the study conducted in United States, the prevalence of any thromboembolic event was 16% J o u r n a l P r e -p r o o f among all COVID-19 inpatients, 29.4% of ICU patients, and 11.5% of non-ICU patients. [2] A single center study from the Netherlands reported that all patients received prophylactic anticoagulation and the prevalence of patients with VTE as 47% and 3.3% in the ICU and general wards, respectively. [13] Finally, a Spanish study investigating the prevalence of DVT in the general wards found that 14.7% of patients experienced DVT. [14] There are several possibilities for the differences observed in the prevalence of thromboemboli between our study conducted in Japan and previous studies conducted in western populations. First, the ethnic characteristics could for the low prevalence of thromboembolic events. A recent systematic review reported population-wide estimates of annual VTE rates in Korea, Taiwan and Hong Kong to be 13.8, 15.9, and 19.9 per 100,000 population, respectively. The annual estimates for thromboembolic events occurring in these Asian populations were roughly 15-20% of the western population.

[7] Consistent with these results, another study from California reported that Asians and Pacific Islanders had a 3-5 fold lower incidence of symptomatic VTE compared to Caucasians. [8] Because our study was homogenous and included only Japanese patients, this could affect the general prevalence of VTE especially when comparing to more heterogenous populations. It should be mentioned that in comparison with ICU patients J o u r n a l P r e -p r o o f in China [1] , the prevalence of VTE was lower in our report (25% vs. 14.3%). The major difference between the present and Chinese study is the lack of prophylactic anticoagulant use in the latter. The present study adopted the use of prophylactic anticoagulants primarily in ICU patients and this is believed to be the most critical contributing factor leading to the difference in the prevalence of thrombosis reported between the two studies. Second, the characteristics of the present study, including severity and baseline complications, differ from other endemic nations. During the timeframe of this study, the Japanese public health strategy mandated the hospitalization of all patients diagnosed with COVID-19. As a result, the present study may be skewed towards the inclusion of non-severe cases. In fact, only 5.6% of all hospitalized patients in our study were admitted to ICU. Furthermore, in comparison with the US study described above, the present study is characterized by younger age groups (median age, 64 vs. 42, US versus Japan, respectively), and a lower prevalence of baseline complications such as diabetes mellitus (37.4% vs. 11.9%) and hypertension (50.3% vs.

18.8%). [2] Third, relatively low BMI is one of the outstanding characteristics in the present study. The median BMI is 22.8 kg/m 2 , which is lower in comparison with previous studies (26.9-30kg/m 2 ). [13] [14] [15] [16] Because obesity is a risk factor for VTE, a lower BMI could have contributed to a lower prevalence of thromboembolic J o u r n a l P r e -p r o o f events. [17] [18] [19] Our study shows that the prevalence of any thromboembolic event was low in Japan, despite the relatively low proportion of patients receiving prophylactic anticoagulation therapy. Prophylactic anticoagulation therapy for all hospitalized patients may not be warranted in Japan as recommended in western guidelines. The present study indicates an increasing prevalence in thromboembolic events consistent with progression in clinical severity. These results may advocate the recommendation of prophylactic anticoagulation therapy in severe and critical categories of disease; however, in asymptomatic, mild and moderate patients, the benefits of the practice of prophylaxis are questionable.

Overall mortality of COVID-19 patients in Japan is lower than in any other western populations [20] ; however, the reasons for this remains unknown. The relatively low prevalence of thromboembolic events in the present study may have contributed to the low mortality of COVID-19 patients in Japan.

Several limitations should be addressed regarding our study. First, the present was a retrospective study utilizing patient data obtained from only two healthcare facilities in Tokyo, Japan. Therefore, the results of the present study may not be an accurate representation of the general status in Japan. Additionally, the number of 8 Data are shown as number (%) or median (interquartile range). 9 IQR, interquartile range 

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Thrombosis in Hospitalized Patients with COVID-19 in a New York City Health System

Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Antithrombotic Therapy in Patients with COVID-19

Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review

Effects of race and ethnicity on the incidence of venous thromboembolism

Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN

Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis

Clinical management of COVID-19

Serial 2-Point Ultrasonography Plus D-Dimer vs Whole-Leg Color-Coded Doppler Ultrasonography for Diagnosing Suspected Symptomatic Deep Vein Thrombosis

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels

Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors

Pulmonary Embolism in Patients with COVID-19: Awareness of an Increased Prevalence

An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: The sirius study

Cardiovascular risk factors and venous thromboembolism: A meta-analysis

Risk factors for venous thromboembolism: Results from the copenhagen city heart study

COVID-19 and Excess All-Cause Mortality in the US and 18 Comparison Countries

COVID-19, coronavirus disease 2019; WHO, World Health Organization; PT

None declared